Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Entera Bio (ENTX) FCF Margin (2019 - 2025)

Entera Bio has reported FCF Margin over the past 6 years, most recently at 3361.9% for Q1 2025.

  • For the quarter ending Q1 2025, FCF Margin changed N/A year-over-year to 3361.9%, compared with a TTM value of 17802.38% through Dec 2025, down 1403387.0%, and an annual FY2025 reading of 17802.38%, down 1403387.0% over the prior year.
  • FCF Margin came in at 3361.9% for Q1 2025, down from 1792.68% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1478.34% in Q1 2021 to a low of 35887.5% in Q3 2022.
  • Median FCF Margin over the past 4 years was 2852.01% (2024), compared with a mean of 6909.31%.
  • The sharpest move saw FCF Margin surged 483490bps in 2021, then plummeted -3437607bps in 2022.
  • Over 4 years, FCF Margin stood at 1528.48% in 2021, then tumbled by -841bps to 14385.71% in 2022, then surged by 88bps to 1792.68% in 2024, then plummeted by -88bps to 3361.9% in 2025.
  • Per Business Quant, the three most recent readings for ENTX's FCF Margin are 3361.9% (Q1 2025), 1792.68% (Q4 2024), and 5128.57% (Q3 2024).